ClinicalTrials.Veeva

Menu

Pazopanib Maintenance for SCLC

Samsung Medical Center logo

Samsung Medical Center

Status and phase

Completed
Phase 2

Conditions

SCLC

Treatments

Drug: Pazopanib
Drug: Placebo

Study type

Interventional

Funder types

Other

Identifiers

NCT01797874
2012-09-060-002

Details and patient eligibility

About

To evaluate the efficacy of pazopanib maintenance after 1st line CTx for SCLC.

Enrollment

97 patients

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • histologically confirmed SCLC
  • no disease progression after 4 cycles of etoposide/platinum 1st-line therapy
  • history of 4 cycles of etoposide/platinum 1st-line therapy
  • between 21 days and 42 days since C4D1 of etoposide/platinum
  • no symptomatic brain meta

Exclusion criteria

  • poor hepatic, renal function

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

97 participants in 2 patient groups, including a placebo group

Pazopanib
Experimental group
Description:
pazopanib maintenance after 4 cycles of etoposide/platinum in SCLC
Treatment:
Drug: Pazopanib
placebo
Placebo Comparator group
Description:
placebo after 4 cycles of etoposide/platinum chemotherapy in SCLC
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems